Fundamentals · ISRG
Valuation Summary for ISRG
AI-generated plain-English read of valuation summary for ISRG. Updated daily.
Expensive multiples, compressing
moderateExpensive multiples (55.3x) that are actively compressing — re-rating risk is the dominant theme. The market is withdrawing the premium; don't catch the falling multiple.
What will probably happen
- Multiple compression is ongoing — expect continued price pressure unless earnings revisions reverse the trend.
What to do
- If you HOLD this stock
- Valuation doesn't give a strong signal for or against adding. Hold and monitor earnings delivery against the current multiple.
- If you're EVALUATING this stock
- Expensive entry. If you must own it, wait for a 10–15% multiple compression or a significant earnings beat that 'grows into' the valuation.
- If you trade OPTIONS
- Sell covered calls to reduce effective cost basis while waiting for multiple normalisation. Long puts make sense if you expect a near-term earnings miss to catalyse compression.
9 quarters / 3 populated multiples — directionally informative; use more data for full conviction.
Technical details
Technical analysis
- P/E (trailing)
- 55.3x
- P/E (forward)
- —
- EV/EBITDA
- —
- P/Sales
- 15.7x
- P/Book
- 9.4x
- EV/Revenue
- —
- FCF yield
- —
- Earnings yield
- —
- Dividend yield
- —
- Absolute valuation
- Expensive
- Sector comparison
- Unknown Vs Sector
- Multiple trajectory
- Compressing
- Income profile
- Growth Profile
- History (quarters)
- 9
- Sector context
- Health Care
Key levels
| Level | Value |
|---|---|
| pe ratio | 55.308 |
| ps ratio | 15.674 |
| pb ratio | 9.426 |
| prior year pe | 72.41 |
| n quarters | 9 |
Caveats
- Multiples should be read alongside growth and quality metrics — a low P/E on declining earnings isn't cheap, it's a value trap warning.
- Sector context wasn't provided — absolute multiples may mislead without industry comparison.